Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bladder carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    316 result(s) found for: Bladder carcinoma. Displaying page 1 of 16.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-004465-33 Sponsor Protocol Number: Cox052006 Start Date*: 2006-12-04
    Sponsor Name:Eero Kaasinen
    Full Title: Oral Celecoxib combined with BCG instillation therapy in treatment of carcinoma in situ (CIS), TaG3 and T1 disease of urinary bladder
    Medical condition: invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10005014 Bladder carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-005431-15 Sponsor Protocol Number: ML 5220 Start Date*: 2008-12-24
    Sponsor Name:ACHG-K.U.Leuven
    Full Title: PHASE III RANDOMIZED CHEMOPREVENTION STUDY OF SELENIUM ON THE RECURRENCE OF NON-INVASIVE BLADDER CANCER
    Medical condition: Bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005014 Bladder carcinoma LLT
    9.1 10005003 Bladder cancer LLT
    9.1 10005004 Bladder cancer NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002259-15 Sponsor Protocol Number: PCB305/04 Start Date*: 2005-01-24
    Sponsor Name:Photocure ASA
    Full Title: A RANDOMIZED, COMPARATIVE,CONTROLLED PHASE III, MULTICENTER STUDY OF HEXVIX FLUORESCENCE CYSTOSCOPY ANDWHITE LIGHT CYSTOSCOPY IN THE DETECTION OF PAPILLARY BLADDER CANCER AND THE EARLYRECURRENCE RA...
    Medical condition: Malignant neoplasm of bladder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10046518 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000782-35 Sponsor Protocol Number: 28-02 (ZKS000429) Start Date*: 2009-01-21
    Sponsor Name:Verein fuer Krebsfoschung (Society for Cancer Research)
    Full Title: Dose-escalating study to determine the maximum tolerated dose (MTD) of the mistletoe extract WEME 200 mg for intravesical instillation in patients with completely resected (R0) superficial bladder ...
    Medical condition: Patients after transurethral R0-resection (TUR) of a histologically confirmed superficial bladder carcinoma (pTa low grade [multilocular or recurrence], pT1 low grade); re-resections included.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046518 Urinary bladder carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001775-35 Sponsor Protocol Number: MC-BCG.4/HBCA Start Date*: 2007-07-12
    Sponsor Name:medac GmbH
    Full Title: Intravesical instillation of BCG strain RIVM versus TICE for prevention of recurrenec in patients with high-risk papillary superficial carcinomas of the urinary bladder. A randomised phase II clini...
    Medical condition: immunostimulating adjuvant therapy of superficial carcinomas of the urinary bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046518 Urinary bladder carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000081-33 Sponsor Protocol Number: JaNEO-001 Start Date*: 2016-05-04
    Sponsor Name:Ligartis GmbH
    Full Title: Phase Ib/II study assessing the neo-adjuvant combination therapy of vinflunine with cisplatin followed by radical cystectomy in patients with muscle-invasive bladder cancer
    Medical condition: Patients with muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005010 Bladder cancer stage II PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005011 Bladder cancer stage III PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005012 Bladder cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001811-59 Sponsor Protocol Number: D933RC00001 Start Date*: 2019-02-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Du...
    Medical condition: Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005010 Bladder cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005011 Bladder cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004876-16 Sponsor Protocol Number: SURE-02 Start Date*: 2021-11-10
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-ba...
    Medical condition: muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003625-17 Sponsor Protocol Number: CA209-275 Start Date*: 2015-01-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agen...
    Medical condition: metastatic or unresectable urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046723 Urothelial carcinoma ureter LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046728 Urothelial carcinoma urethra LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) BE (Completed) SE (Completed) CZ (Completed) FI (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002760-16 Sponsor Protocol Number: 04/QO603/42 HEXVIX Start Date*: 2005-01-12
    Sponsor Name:Guy's and St Thomas' NHS Foundation Trust
    Full Title: A randomised Study of “bluelight” hexyl amino levulinic acid (HAL) photodynamic assisted resection of bladder tumours versus conventional “white light” transurethral resection of newly diagnosed bl...
    Medical condition: Superficial Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005003 Bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-018246-38 Sponsor Protocol Number: Jun_11_2009_Updated_Nov_2009 Start Date*: 2010-12-23
    Sponsor Name:Antoni van Leeuwenhoek Ziekenhuis
    Full Title: Phase II trial evaluating combined image guided radiotherapy with Panitumumab (Vectibix®) in patients with muscle invasive transitional cell carcinoma of the bladder
    Medical condition: patients with muscle invasive transitional cell carcinoma of the bladder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10005017 Bladder carcinoma stage 0, with cancer in situ LLT
    12.1 10005019 Bladder carcinoma stage I, with cancer in situ LLT
    12.1 10005021 Bladder carcinoma stage II LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003517-42 Sponsor Protocol Number: SPI-1012 Start Date*: 2011-11-23
    Sponsor Name:Spectrum Pharmaceuticals, Inc
    Full Title: A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patie...
    Medical condition: The medical condition under investigation is noninvasive bladder cancer in patients undergoing transurethral resection of bladder tumor/tumors.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005007 Bladder cancer stage 0, without cancer in situ PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000687-89 Sponsor Protocol Number: ICR-CTSU/2008/10018 Start Date*: 2006-11-20
    Sponsor Name:Institute of Cancer Research
    Full Title: A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder
    Medical condition: Non-muscle Invasive Transitional cell Carcinoma of the Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000150-22 Sponsor Protocol Number: T14/2018 Start Date*: 2018-06-05
    Sponsor Name:Turku University Hospital
    Full Title: Intravesical instillation therapy with bacillus Calmette-Guérin (BCG) and sequential BCG and electromotive Mitomycin-C (EMDA-MCC) in patients with high risk non-muscle-invasive bladder carcinoma
    Medical condition: Non-muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015404-26 Sponsor Protocol Number: SPI-611 Start Date*: 2009-11-12
    Sponsor Name:Spectrum Pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial of Single-Dose Intravesical EOquinâ as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoi...
    Medical condition: The medical condition under investigation is noninvasive bladder cancer in patients undergoing transurethral resection of bladder tumor.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005005 Bladder cancer recurrent LLT
    9.1 10005007 Bladder cancer stage 0, without cancer in situ LLT
    9.1 10005003 Bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022653-41 Sponsor Protocol Number: INT52/10 Start Date*: 2010-11-25
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for patients with transitional cell carcinoma of the bladder.
    Medical condition: Muscle-invasive transitional cell carcinoma of the bladder at clinical stage T>/=2N0.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005084 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001942-42 Sponsor Protocol Number: GEMCITABINA INTRAVESCICALE Start Date*: 2007-04-26
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: Pharmacokinetical-clinical study of intravescical gemcitabine in patients with marker lesion of superficial transitional cell carcinoma of the bladder
    Medical condition: Patients with superficial transitional cell carcinoma of the bladder
    Disease: Version SOC Term Classification Code Term Level
    6.1 10005003 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005263-27 Sponsor Protocol Number: IPOI-VS-IPOP Start Date*: 2014-01-22
    Sponsor Name:CHU POITIERS
    Full Title: EVALUATION OF EARLY PRE-OPERATIVE INTRAVESICAL INSTILLATION OF MYTOMYCIN-C AFTER TRANSURETHRAL RESECTION OF BLADDER TUMOR COMPARED TO EARLY POST-OPERATIVE INSTILLATION. A RANDOMIZED MULTICENTER ST...
    Medical condition: NON-MUSCLE INVASIVE BLADDER CANCER
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000607-41 Sponsor Protocol Number: MMC-BCG-1 Start Date*: 2011-03-04
    Sponsor Name:Centre Hospitalier de Jolimont-Lobbes-Tubize-Nivelles
    Full Title: A phase I/II multicentric Belgian prospective novel sequential chemo-immunotherapy regimen for adjuvant treatment in non-muscle invasive bladder cancer.
    Medical condition: Patients with intermediate/high risk non-muscle invasive bladder cancer (NMIBC) • intermediate risk tumours – Ta, T1 Grade 1, Grade 2, multifocal and tumours larger than 3 cm • high risk tumours – ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003898-98 Sponsor Protocol Number: PDD_vs_WL-TURB_in_pazienti_con_NMIB Start Date*: 2013-11-28
    Sponsor Name:Ospedale San Raffaele
    Full Title: COMPARISON OF WHITE LIGHT TUR VS PHOTODYNAMIC DIAGNOSIS (PDD)- GUIDED TUR AS ASSESSED BY SECOND LOOK TUR FOR THE TREATMENT OF HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Medical condition: high grade non muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:11:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA